++
For further information, see CMDT Part 25-05: Anxiety Disorders
+++
Essentials of Diagnosis
++
Persistent excessive anxiety or chronic fear and associated behavioral disturbances
Somatic symptoms referable to the autonomic nervous system or to a specific organ system (eg, dyspnea, palpitations, paresthesias)
Not limited to an adjustment disorder
Not a result of physical disorders (eg, hyperthyroidism), other psychiatric conditions (eg, schizophrenia), or drug abuse
+++
General Considerations
++
++
About 7% of women and 4% of men will meet criteria for GAD over a lifetime
Prevalence of panic disorder: 3–5%, 25% with coincident obsessive-compulsive disorder
++
Anxiety or fear
Apprehension or worry
Difficulty concentrating
Insomnia and fatigue
Irritability
Feelings of impending doom
Recurrent thoughts or fears
Repetitive actions and rituals
Avoidant behaviors
Sympathomimetic symptoms
Tachycardia
Hyperventilation
Tremor
Sweating
Somatic symptoms
Paresthesias
Dizziness
Nausea
Chest pain
Palpitations
+++
Differential Diagnosis
++
Hyperthyroidism
Pheochromocytoma
Sympathomimetic drug use
Myocardial infarction
Hypoglycemia
Adjustment disorder
++
++
+++
Diagnostic Procedures
++
++
See Table 25–1
GAD
Antidepressants (including the selective serotonin reuptake inhibitors [SSRIs] and serotonin norepinephrine reuptake inhibitors [SNRIs]) are safe and effective; they appear to be as effective as the benzodiazepines without the risks of tolerance or dependence
SSRIs, such as escitalopram and paroxetine, are FDA-approved
SNRIs
Buspirone
Sometimes used as an augmenting agent in the treatment of depression and compulsive behaviors
Also effective for generalized anxiety
Usually given in a total dose of 30–60 mg/day in divided doses
Higher doses are sometimes associated with side effects of gastrointestinal symptoms and dizziness
Gabapentin (titrated to doses of 900–1800 mg orally daily, with larger doses at night) and pregabalin
Panic disorder
SSRIs
Fluoxetine
Paroxetine
Sertraline
SNRI
Benzodiazepines